Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH815 in Advanced Solid Tumors
NCT06885645Phase 1Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of KH815 in solid tumor (advanced stage), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 12 months, Dose Limiting Toxicities at 21 days and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
KH815
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06885645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885645.